Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan

Lorenzo Fornaro (1) , Francesco Leone (2) , Angélique Vienot (3) , Andrea Casadei-Gardini (4) , Caterina Vivaldi (1) , Astrid Lièvre (5) , Pasquale Lombardi (2) , Emmanuele de Luca (6) , Dewi Vernerey (7) , Elisa Sperti , Gianna Musettini (1) , Maria Antonietta Satolli (6) , Julien Edeline (8) , Rosella Spadi , Cindy Neuzillet (9) , Alfredo Falcone (1) , Giulia Pasquini (1) , Mario Clerico , Alessandro Passardi (2) , Paola Buscaglia , Aurélia Meurisse (7) , Massimo Aglietta (2) , Clémence Brac (10) , Enrico Vasile (1) , Francesco Montagnani

1 Azienda Ospedaliera Universitaria Pisana
2 IRCCS - Istituti di Ricovero e Cura a Carattere Scientifico
3 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
4 UNIMORE - Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia
5 COSS - Chemistry, Oncogenesis, Stress and Signaling
6 UNITO - Università degli studi di Torino = University of Turin
7 CEF2P / CARCINO - Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181)
8 NuMeCan - Nutrition, Métabolismes et Cancer
9 Institut Curie [Paris]
10 CRLCC - CRLCC Eugène Marquis

BACKGROUND:FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit patients with metastatic (MPC) and locally advanced unresectable (LAPC) pancreatic cancer. However, no criteria reliably identify patients with better outcomes.PATIENTS AND METHODS:We investigated putative prognostic factors among 137 MPC/LAPC patients treated with triplet chemotherapy. Association with 6-month survival status (primary endpoint) was assessed by multivariate logistic regression models. A nomogram predicting the risk of death at 6 months was built by assigning a numeric score to each identified variable, weighted on its level of association with survival. External validation was performed in an independent data set of 206 patients. The study was registered at ClinicalTrials.gov (NCT03590275).RESULTS:Four variables (performance status, liver metastases, baseline carbohydrate antigen 19-9 level, and neutrophil-to-lymphocyte ratio) were found to be associated with 6-month survival by multivariate analysis or had sufficient clinical plausibility to be included in the nomogram. Accuracy was confirmed in the validation cohort (C index = 0.762; 95% confidence interval, 0.713-0.825). After grouping all cases, 4 subsets with different outcomes were identified by 0, 1, 2, or > 2 poor prognostic features (P < .0001).CONCLUSION:The nomogram we constructed accurately predicts the risk of death in the first 6 months after initiation of FOLFIRINOX in MPC/LAPC patients. This tool could be useful to guide communication about prognosis, and to inform the design and interpretation of clinical trials.

Mots clés: FOLFIRINOX; Clinical parameters; Laboratory parameters; Risk categories; Prognosis

Domaines: Sciences du Vivant [q-bio]; Cancer; Hépatologie et Gastroentérologie

Lorenzo Fornaro, Francesco Leone, Angélique Vienot, Andrea Casadei-Gardini, Caterina Vivaldi, et al.. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Clinical Colorectal Cancer, 2019, 18 (4), pp.e394-e401. ⟨10.1016/j.clcc.2019.08.004⟩. ⟨hal-02307162⟩